Get 40% Off
🤯 Perficient is up a mind-blowing 53%. Our ProPicks AI saw the buying opportunity in March.Read full update

Takeda shareholder group aims to block $62 billion Shire deal

Published 11/06/2018, 14:08
© Reuters. FILE PHOTO:  Shire branding is seen outside their offices in Dublin

By Sam Nussey

TOKYO (Reuters) - A group of Takeda Pharmaceutical Co Ltd (T:4502) shareholders is trying to build support to block the $62 billion (46.4 billion pounds) acquisition of London-listed Shire Plc (L:SHP) at an extraordinary general meeting, a leading member of the group told Reuters on Monday.

Takeda will hold the shareholder meeting later this year or early next year to approve an issue of new stock to help fund the Shire deal, making it a de facto vote on the deal itself.

The 130 member group formed by ex-Takeda employees holds one percent of the drugmaker's shares, and needs to secure a third of shareholder votes.

It is "working steadily to increase support" for blocking the deal among domestic retail investors and overseas institutional investors who own 25 percent and 35 percent of Takeda shares respectively, the person said on condition of anonymity.

The group includes members of the founding Takeda family, Nikkan Yakugyo reported last month. The family owns about 10 percent of Takeda shares, people familiar with the matter told Reuters.

Last year, the same group attempted to prevent the appointment of outgoing Chairman Yasuchika Hasegawa to an advisory position at the company. Although the proposal was defeated at the company's annual general meeting, it gained 30.5 percent of votes.

The group has a proposal at this month's annual general meeting too, arguing that deals worth more than 1 trillion yen ($9.1 billion) should be put to a shareholder vote.

It does not expect that proposal to pass either, but hopes it will help draw attention to "what an irrational deal" the Shire transaction is, the group member said.

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

The group argues Takeda is taking on too much financial risk with the acquisition and says Shire's haemophilia franchise is threatened by Roche Holding AG's (S:ROG) new haemophilia drug Hemlibra.

Takeda Chief Executive Christophe Weber has expressed confidence shareholders will vote in favour of the deal.

Shares at the drugmaker have fallen more than 20 percent since it first said it was considering bidding for Shire.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.